Research And Markets Research And Markets
0 CHECKOUT

Respiratory Depression - Pipeline Review, H1 2015

  • ID: 3164987
  • March 2015
  • 41 pages
  • Global Markets Direct
1 of 4

Respiratory Depression - Pipeline Review, H1 2015

Summary

This, ‘Respiratory Depression - Pipeline Review, H1 2015’, provides an overview of the Respiratory Depression’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Respiratory Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Depression and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser READ MORE >

Note: Product cover images may vary from those shown
2 of 4

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Respiratory Depression Overview
Therapeutics Development
Pipeline Products for Respiratory Depression - Overview
Pipeline Products for Respiratory Depression - Comparative Analysis
Respiratory Depression - Therapeutics under Development by Companies
Respiratory Depression - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Respiratory Depression - Products under Development by Companies
Respiratory Depression - Companies Involved in Therapeutics Development
Cortex Pharmaceuticals, Inc.
Galleon Pharmaceuticals
Respiratory Depression - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CX-1739 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CX-1942 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CX-2007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CX-2076 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
doxapram hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GAL-021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GAL-021 Successors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tianeptine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Respiratory Depression - Recent Pipeline Updates
Respiratory Depression - Dormant Projects
Respiratory Depression - Product Development Milestones
Featured News & Press Releases
Sep 24, 2014: Cortex Pharmaceuticals Announces Phase 1 Funding by the National Institute of Drug Abuse, National Institutes of Health, Under the Small Business Innovation Research Funding Award Program
Feb 12, 2014: Revive Therapeutics Announces Encouraging Interim Results from Ongoing Phase 2a Proof-Of-Concept Study of REV-001 for the Prevention of Opioid-Induced Respiratory Depression
Sep 20, 2012: Galleon Pharma Reports Positive Results From Second Phase I Study Of GAL-021 For Treatment Of Respiratory Depression
May 07, 2012: Galleon Reports Positive Results From Phase I Study Of GAL-021 For Treatment Of Respiratory Depression
Aug 24, 2011: Cortex Receives US Patent For Use Of Ampakine Molecules To Treat Respiratory Depression
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Respiratory Depression, H1 2015
Number of Products under Development for Respiratory Depression - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Respiratory Depression - Pipeline by Cortex Pharmaceuticals, Inc., H1 2015
Respiratory Depression - Pipeline by Galleon Pharmaceuticals, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Respiratory Depression Therapeutics - Recent Pipeline Updates, H1 2015
Respiratory Depression - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Respiratory Depression, H1 2015
Number of Products under Development for Respiratory Depression - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Cortex Pharmaceuticals, Inc.
Galleon Pharmaceuticals

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db